Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that CEO Axel Bolte will be part of the Neuromuscular and Bone Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, from 2:10-3:10 pm ET in Boston. The event will highlight the company’s innovative therapeutic initiatives aimed at treating pathologic mineralization and intimal proliferation. A replay of the panel will be available on their Investor Relations page for a limited time after the event. Inozyme is developing INZ-701, currently in Phase 1/2 trials for ENPP1 and ABCC6 Deficiencies.

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in the Neuromuscular and Bone Panel presentation at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023, from 2:10-3:10pm ET in Boston.

A replay of the panel presentation can be accessed from the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

FAQ

What is the date and time of Inozyme Pharma's presentation at the Cowen 43rd Annual Health Care Conference?

Inozyme Pharma's presentation is scheduled for March 8, 2023, from 2:10 to 3:10 pm ET.

Who will represent Inozyme Pharma at the Cowen 43rd Annual Health Care Conference?

CEO Axel Bolte will represent Inozyme Pharma at the conference.

Where can I access the replay of Inozyme Pharma's panel presentation?

The replay can be accessed on the Investor Relations section of Inozyme's website.

What is the focus of Inozyme Pharma's development efforts?

Inozyme Pharma focuses on developing novel therapeutics for pathologic mineralization and intimal proliferation.

What is the status of Inozyme Pharma's drug INZ-701?

INZ-701 is currently in Phase 1/2 clinical trials for treating ENPP1 and ABCC6 deficiencies.